Drugs / NST-1024
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05368831 | Jul → Sep 2022 | — | NorthSea Therapeutics B.V. | Completed | No outcome recorded |
| Phase 1 | NCT04630366 | Oct 2020 → Jun 2022 | hypertriglyceridemia | NorthSea Therapeutics B.V. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05889156 Comparator | Jun 2023 → Mar 2025 | hypertriglyceridemia | NorthSea Therapeutics B.V. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NST-1024 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04630366 ↗ |
| Route | Oral | “single and multiple oral dose study” NCT04630366 ↗ |